Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 13:25
04/09/20
04/09
13:25
04/09/20
13:25
AMRN

Amarin

$6.14 /

+0.33 (+5.68%)

, MTNB

Matinas BioPharma

$0.55 /

+0.0134 (+2.50%)

Biotechnology Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Theravance joining fight against COVID-19 with TD-0903, says Piper Sandler » 12:46
04/09/20
04/09
12:46
04/09/20
12:46
TBPH

Theravance Biopharma

$24.23 /

+0.73 (+3.11%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Nevro says court upholds patent claims validity in Boston Scientific case » 12:45
04/09/20
04/09
12:45
04/09/20
12:45
NVRO

Nevro

$108.49 /

+0.2 (+0.18%)

, BSX

Boston Scientific

$36.27 /

+1.16 (+3.30%)

Nevro (NVRO) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analysts to hold an analyst/industry conference call » 11:25
04/09/20
04/09
11:25
04/09/20
11:25
ARCT

Arcturus Therapeutics

$14.17 /

+0.34 (+2.46%)

Analysts discuss Arcturus…

Analysts discuss Arcturus Therapeutics' LUNAR-COV19 vaccine candidate and how STARR technology can induce immunity at low levels of dosed mRNA on an Analyst/Industry conference call to be held on April 9 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Constellation Pharmaceuticals participates in a conference call with SunTrust » 11:25
04/09/20
04/09
11:25
04/09/20
11:25
CNST

Constellation Pharmaceuticals

$33.08 /

+1.04 (+3.25%)

Healthcare Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Bernstein to hold a webinar » 10:50
04/09/20
04/09
10:50
04/09/20
10:50
AMGN

Amgen

$215.84 /

-3.4 (-1.55%)

, ADPT

Adaptive Biotechnologies

$24.91 /

-0.19 (-0.76%)

Amgen and Adaptive…

Amgen and Adaptive Biotechnologies participate in a webinar on their strategic collaboration to develop a therapeutic to prevent or treat COVID-19 on April 9 at 11 am hosted by Bernstein. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Fly Intel: Top five analyst initiations » 10:16
04/09/20
04/09
10:16
04/09/20
10:16
CUE

Cue Biopharma

$17.71 /

+1.2 (+7.27%)

, GSS

Golden Star Resources

$2.46 /

+0.055 (+2.29%)

, CARR

Carrier Global

$14.82 /

+0.61 (+4.29%)

, POST

Post Holdings

$90.59 /

+1.54 (+1.73%)

, PRVL

Prevail Therapeutics

$14.60 /

+0.81 (+5.87%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cue Biopharma (CUE) initiated with a Buy at Stifel. 2. Golden Star Resources (GSS) initiated with a Market Perform at BMO Capital. 3. Carrier Global (CARR) initiated with an Equal Weight at Barclays. 4. Post Holdings (POST) assumed with a Buy at Citi. 5. Prevail Therapeutics (PRVL) initiated with an Overweight at Piper Sandler. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Iovance 'could be name to keep eye on' if Gilead seeks M&A, Dealreporter says » 09:47
04/09/20
04/09
09:47
04/09/20
09:47
IOVA

Iovance Biotherapeutics

$31.24 /

+0.34 (+1.10%)

, GILD

Gilead

$74.03 /

-0.95 (-1.27%)

After Gilead (GILD) gave…

After Gilead (GILD) gave soft guidance for this year, Dealreporter told its readers that if the pharma giant "were to go back to the well in oncology, Iovance Biotherapeutics (IOVA) could be a name to keep an eye on," sources tell The Fly. The biotech company reportedly saw some interest in February and such a hypothetical deal would give Gilead "another shot on goal in cell therapy" to build on its prior acquisition of Kite Pharma, the report added, according to contacts.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Stereotaxis participates in a conference call hosted by Lake Street » 09:29
04/09/20
04/09
09:29
04/09/20
09:29
STXS

Stereotaxis

$2.72 /

-0.23 (-7.80%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital » 09:27
04/09/20
04/09
09:27
04/09/20
09:27
SAGE

Sage Therapeutics

$30.00 /

+1.16 (+4.02%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman lowered the firm's price target on Sage Therapeutics to $65 from $86 but keeps an Outperform rating on the shares. The analyst says the company's corporate restructuring announcement to free up $170M in cost savings is not surprising given the uncertain COVID-19 environment, adding that he agrees with the decision to prioritize resources to higher-value opportunities in the pipeline. Nachman also cuts his FY20 and FY21 EPS views on Sage to ($8.25) from ($9.39) and to ($5.67) from ($7.25).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.